Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis.
Candesant Biomedical has raised $35.0M in total funding. The most recent round was Series B. The last funding was announced in June 2023.
Candesant Biomedical's investors include Polaris Partners, Correlation Ventures, Astia, KCK Medtech.
Candesant Biomedical is headquartered in San Francisco, United States.
Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis.
Candesant Biomedical is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Candesant Biomedical — Funding & Investors." VCBacked, June 6, 2023, https://www.vcbacked.co/company/candesant-biomedical. Accessed November 19, 2026.
VCBacked. (2023). Candesant Biomedical — Funding & Investors. Retrieved November 19, 2026, from https://www.vcbacked.co/company/candesant-biomedical
{{cite web |title=Candesant Biomedical — Funding & Investors |url=https://www.vcbacked.co/company/candesant-biomedical |website=VCBacked |access-date=November 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Candesant Biomedical? Request a listing update